177 related articles for article (PubMed ID: 26119219)
1. [Radioresistance parameters in head and neck cancers and methods to radiosensitize].
Biau J; Chautard E; Miroir J; Lapeyre M
Cancer Radiother; 2015 Aug; 19(5):337-46; quiz 360-1, 363. PubMed ID: 26119219
[TBL] [Abstract][Full Text] [Related]
2. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
3. [Radiosensitivity and/or radioresistance of head and neck cancers: Biological angle].
Guy JB; Rancoule C; Méry B; Espenel S; Wozny AS; Simonet S; Vallard A; Alphonse G; Ardail D; Rodriguez-Lafrasse C; Magné N
Bull Cancer; 2016 Jan; 103(1):41-7. PubMed ID: 26702507
[TBL] [Abstract][Full Text] [Related]
4. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy.
Hoff CM
Acta Oncol; 2012 Apr; 51(4):419-32. PubMed ID: 22313317
[TBL] [Abstract][Full Text] [Related]
5. [Radiosensitization of hypoxic tumor cells with special reference to head and neck cancers].
Kogelnik HD
Wien Klin Wochenschr; 1983 Aug; 95(15):515-8. PubMed ID: 6636784
[TBL] [Abstract][Full Text] [Related]
6. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
7. Overcoming radioresistance in head and neck squamous cell carcinoma.
Yamamoto VN; Thylur DS; Bauschard M; Schmale I; Sinha UK
Oral Oncol; 2016 Dec; 63():44-51. PubMed ID: 27938999
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
Koukourakis MI; Giatromanolaki A; Danielidis V; Sivridis E
Int J Radiat Biol; 2008 Jan; 84(1):47-52. PubMed ID: 17852557
[TBL] [Abstract][Full Text] [Related]
9. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
10. [Erythropoietin and radiation therapy].
Hennequin C
Bull Cancer; 2006 May; 93(5):495-9. PubMed ID: 16777628
[TBL] [Abstract][Full Text] [Related]
11. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J; Lefebvre JL; Vermorken JB
Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
[TBL] [Abstract][Full Text] [Related]
14. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
15. Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
Baumann R; Depping R; Delaperriere M; Dunst J
Expert Rev Anticancer Ther; 2016 Jul; 16(7):751-8. PubMed ID: 27253509
[TBL] [Abstract][Full Text] [Related]
16. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
17. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome.
Lassen P
Radiother Oncol; 2010 Jun; 95(3):371-80. PubMed ID: 20493569
[TBL] [Abstract][Full Text] [Related]
18. Impact of anemia in patients with head and neck cancer.
Kumar P
Oncologist; 2000; 5 Suppl 2():13-8. PubMed ID: 10896324
[TBL] [Abstract][Full Text] [Related]
19. The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers.
Björk-Eriksson T; West CM; Cvetskovska E; Svensson M; Karlsson E; Magnusson B; Slevin NJ; Edström S; Mercke C
Br J Cancer; 1999 Jul; 80(9):1400-4. PubMed ID: 10424742
[TBL] [Abstract][Full Text] [Related]
20. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
